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Abstract: Measuring multiple hormones simultaneously in a single assay saves sample volume, labor, time,
reagents, money, and consumables. Thus, multiplex arrays represent a faster, more economically and ecologically sound
alternative to singleton assays.
Objectives: To validate a new, commercially available multiplex female array produced by Quansys Biosciences
against individual immunoassays for the quantiﬁcation of six hormones in urine samples from women in different
reproductive stages.
Methods: Urine samples were analyzed using the new Quansys multiplex female hormone array and compared
with well-established individual immunoassays for adiponectin, free cortisol, c-peptide, estrone-3-glucuronide (E1G),
follicle stimulating hormone beta-subunit (FSH-beta), and human chorionic gonadotropin beta-subunit (hCG-beta).
Correlations between assays were assessed using Pearson correlation, linear regression and Bland–Altman analysis.
The temporal proﬁles of free cortisol, E1G, FSH-beta, and hCG-beta were also compared.
Results: The multiplex array was highly correlated with the individual immunoassays for ﬁve of the tested hor-
mones (Pearson’s correlation coefﬁcient 0.75), and yielded temporal patterns of hormone proﬁles consistent with the
individual immunoassays for free cortisol, E1G, FSH-beta, and hCG-beta.
Conclusions: The Quansys multiplex female hormone array is a valid alternative method to individual immunoassays
for the quantiﬁcation of stress, reproductive and energetic hormones and metabolites in human urine samples and can be used
to examine the dynamic interactions between these hormones. Am. J. Hum. Biol. 24:81–86, 2012. ' 2011Wiley Periodicals, Inc.
Evaluating how everyday psychosocial, energetic, and
environmental challenges affect growth, development,
reproduction, and health can be best achieved by using
longitudinal naturalistic designs. These designs often
involve the collection of a large number of specimens in
difﬁcult ﬁeld conditions. Those specimens need to be prop-
erly stored and later transported to facilities where they
are analyzed. In nonurban ﬁeld sites appropriate storage
space is frequently scarce and transport is logistically dif-
ﬁcult and economically costly. Thus, specimens collected
in those types of settings are both expensive and very val-
uable commodities. Methods that help reduce the
expenses related to their storage and transport are there-
fore important to ﬁelds such as human biology, ecology,
and epidemiology.
Another major expense associated with longitudinal
naturalistic studies is that they usually involve the mea-
surement of multiple biomarkers in each of the numerous
biospecimens collected. Traditionally, quantiﬁcation of
multiple biomarkers has been performed using individual
immunoassays for each biomarker. This process requires
the collection, storage, and preservation of enough sample
volume to assess all the metabolites of interest in separate
assays. Individual analyses are also costly in terms of per-
sonnel time, amount of reagents, and consumables.
To reduce these costs we commissioned Quansys
Biosciences (Logan, UT) to develop a custom-designed
multiplex array for the concurrent quantiﬁcation of physi-
ological biomarkers of stress (free cortisol), energy balance
(adiponectin and c-peptide), and reproductive function [es-
trone-3-glucuronide (E1G), follicle stimulating hormone
beta-subunit (FSH-beta), and human chorionic gonadotro-
pin beta-subunit (hCG-beta)] in ﬁrst morning urine sam-
ples. To that aim Quansys produced a 96-well array based
on sandwich and competitive immunoassays which uses
six antibodies bound in 3 3 2 spot array format to the bot-
tom of each well of a microtiter plate. Here we present our
validation of the Quansys multiplex immunoassay array
based on a comparison with previously established indi-
vidual immunoassays.
The simultaneous quantiﬁcation of multiple biomarkers
allows researchers to store and transport smaller sample
volumes and saves time, reagents, and consumables,
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reducing the amount of waste produced, providing a
faster, greener, and more economic alternative to individ-
ual assays.
METHODS
Two sets of urine samples were used in this validation
study: (1) archived samples collected in the context of the
society, environment and reproduction (SER) study
(Nepomnaschy et al., 2004, 2006) and (2) samples collected
for the calibration of laboratory equipment. This research
was approved by the Research Ethics Board of Simon
Fraser University.
Archived samples
Background on the SER study’s location, participants,
specimen collection, and sample preparation has been pre-
viously published (Nepomnaschy et al., 2004, 2006).
Brieﬂy, urine specimens were collected thrice weekly from
women in a rural Kaqchikel Mayan community located in
the southwest highlands of Guatemala who were parous,
not pregnant, not using any form of chemical contracep-
tive method, and at least 6 months from the birth of their
last child. We restricted our current analysis to a subset of
samples collected from 15 participants in the SER study
who had resumed ovarian cyclicity postpartum and who
had provided at least eight morning urine specimens
(range: 8–39 specimens). A minimum of eight samples
allowed us to generate individual hormone/metabolite pro-
ﬁles for each participant. Samples were preserved at
2108C for up to 6 months in the ﬁeld and then shipped on
dry ice from Guatemala to the CLASS laboratory at the
University of Michigan where they were archived at
2808C. The specimens were originally assayed between
2002 and 2004 in the CLASS laboratory for urinary free
cortisol, estrogen conjugates (E1C), FSH-beta and hCG-
beta (details below). In 2010 samples were shipped on dry
ice to the Maternal and Child Health laboratory at Simon
Fraser University, where they were stored again at 2808C
until analysis using the multiplex assay.
Calibration samples
First morning urine specimens were collected from vol-
unteers (three males aged 35–40; 13 females aged 20–40
in the follicular phase of the ovarian cycle; 15 females
aged 20–40 in the luteal phase; 4 menopausal females
aged 55–75) for the purpose of calibrating laboratory
equipment. All female volunteers were not using any form
of chemical contraceptive method. Aliquots from the origi-
nal specimens were stored at 2808C until analysis using
individual and multiplex immunoassays. Two-ml aliquots
of each sample were transported on dry ice to the Center
for Studies in Demography and Ecology (CSDE) at the
University of Washington and stored at 2208C until anal-
ysis using individual immunoassays.
Immunoassays
Concentrations of urinary free cortisol and reproductive
hormones (E1C, FSH-beta, and hCG-beta) were measured
in the archived samples using immunoassays developed
for use with urine samples and the Bayer Automated
Chemiluminescence System (ACS-180) immunoassay
analyzer in the CLASS laboratory (Nepomnaschy et al.,
2004; Santoro et al., 2003).
Commercial immunoassay kits were used to determine
urinary concentrations of adiponectin (Cat # 40-055-
200002; GenWay Biotech, San Diego, CA), free cortisol
(Cat # ADI-901-071; ENZO Life Sciences, Plymouth Meet-
ing, PA), and c-peptide (Cat # CP179S; Calbiotech, Spring
Valley, CA) in the calibration samples. All three commer-
cial immunoassay kits were designed for use with human
serum, plasma, and urine samples. Concentrations of E1G
and FSH-beta in the calibration samples were measured
using in-house immunoassays developed for use with
urine samples by the CSDE laboratory (Brindle et al.,
2006; O’Connor et al., 2004).
A variety of different multiplex technologies exist for
the simultaneous identiﬁcation and quantiﬁcation of mul-
tiple biomarkers in the same sample. ELISA/EIA microar-
rays, including the Q-plex technology used by Quansys,
involve the spotting of antibodies created against different
biomarkers onto glass, nitrocellulose or 96-well plates.
Flow cytometry-based assays involve conjugating these
antibodies to microsphere beads and mixing different com-
binations of antibody-bound beads together to create a
multiplex assay. Both technologies are essentially micro-
ELISA/EIAs within a well or on a bead. Many different
companies sell multiplex arrays for a variety to analytes
(e.g., cytokines, reproductive hormones, angiogenesis bio-
markers). Thus, the technology for creating ELISA/EIA
microarrays is widely available. The speciﬁc array we
have validated is commercially available from the afore-
mentioned company.
Each archived and calibration urine sample was ana-
lyzed using the Quansys multiplex female hormone
array at the Maternal and Child Health Laboratory at
SFU. Each of the assays within the multiplex array
works either as a sandwich or competitive immunoassay.
Each of the six spots within each well contains a distinct
capture antibody population. For the sandwich immuno-
assays (adiponectin, c-peptide, FSH-beta, hCG-beta) the
biomarkers in each sample bind to their distinct capture
antibody spots and are subsequently bound by bio-
marker-speciﬁc, horseradish peroxidase (HRP)-bound
secondary antibodies. For the competitive assays (free
cortisol, E1G), the biomarkers in each sample compete
with HRP-conjugated forms of the biomarkers to bind to
their distinct capture antibody spots. Following the addi-
tion of substrate to each well, the HRP activity and
resulting chemiluminescence of each spot is directly
(sandwich assay) or indirectly (competitive assay) pro-
portional to the concentration of biomarker in the sam-
ple. To determine the biomarker concentration in each
sample, an image of the plate is taken by the Quansys
Q-view imager system, which includes a high-resolution
Canon digital camera, and the intensity of the chemilu-
minescence of each spot is compared to that of a seven-
point standard curve generated using ﬁve-parameter
logistic regression for that particular biomarker using
Quansys Q-view software.
For all multiplex and individual assays, samples were
run in duplicate wells. Outliers were identiﬁed as data
points for which the coefﬁcient of variation was >12%
between duplicates, and the samples were rerun. The
standard ranges, sensitivities and precision of the
Quansys multiplex array and the individual immunoas-
says are presented in Table 1.
82 K.G. SALVANTE ET AL.
American Journal of Human Biology
T
A
B
L
E
1
.
C
om
p
a
ri
so
n
of
th
e
Q
u
a
n
sy
s
m
u
lt
ip
le
x
im
m
u
n
oa
ss
a
y
a
rr
a
y
a
n
d
in
d
iv
id
u
a
l
im
m
u
n
oa
ss
a
ys
H
or
m
on
e
Q
u
a
n
sy
s
m
u
lt
ip
le
x
a
rr
a
y
ra
n
g
e,
se
n
si
ti
v
it
y
a
n
d
p
re
ci
si
on
In
d
iv
id
u
a
l
im
m
u
n
oa
ss
a
y
ra
n
g
e,
se
n
si
ti
v
it
y
a
n
d
p
re
ci
si
on
C
om
p
a
ri
so
n
of
th
e
Q
u
a
n
sy
s
m
u
lt
ip
le
x
a
rr
a
y
w
it
h
in
d
iv
id
u
a
l
im
m
u
n
oa
ss
a
y
s
S
ta
n
d
a
rd
ra
n
g
e
S
en
si
ti
v
it
y
In
tr
a
-
a
ss
a
y
C
V
In
te
r-
a
ss
a
y
C
V
C
om
p
a
n
y
S
ta
n
d
a
rd
ra
n
g
e
S
en
si
ti
v
it
y
In
tr
a
-
a
ss
a
y
C
V
In
te
r-
a
ss
a
y
C
V
n
(u
ri
n
e
se
t)
T
re
n
d
li
n
es
P
ea
rs
on
co
rr
el
a
ti
on
(r
)
A
d
ip
on
ec
ti
n
0
.0
3
9
–
2
8
.3
0
0
n
g
m
l2
1
0
.0
2
3
n
g
m
l2
1
L
8
.7
%
;
M
11
.0
%
;
H
1
0
.4
%
L
4
.7
%
;
M
7
.1
%
;
H
8
.9
%
G
en
w
a
y
1
.0
0
–
5
0
.0
n
g
m
l2
1
0
.1
5
6
n
g
m
l2
1
4
.4
%
6
.2
%
1
0
(c
a
li
b
)
lo
g
y
5
1
.4
6
9
(l
og
x)
1
0
.3
1
5
0
.9
3
5
*
fr
ee
co
rt
is
ol
1
.0
1
8
–
7
4
2
.0
0
0
n
g
m
l2
1
0
.3
4
3
n
g
m
l2
1
L
7
.4
%
;
M
6
.7
%
;
H
7
.3
%
L
6
.7
%
;
M
6
.7
%
;
H
1
2
.1
%
E
N
Z
O
0
.1
5
6
–
1
0
.0
n
g
m
l2
1
0
.0
5
7
n
g
m
l2
1
1
0
.5
%
1
3
.4
%
3
5
(c
a
li
b
)
lo
g
y
5
0
.8
0
2
(l
og
x)
1
1
.7
5
9
0
.7
8
0
*
B
a
y
er
A
C
S
:1
8
0
2
.0
–
7
5
0
.0
n
g
m
l2
1
2
.0
n
g
m
l2
1
2
.0
%
6
.5
%
3
2
0
(a
rc
h
iv
)
lo
g
y
5
1
.2
4
7
(l
og
x)
1
0
.3
1
2
0
.9
2
2
*
c-
p
ep
ti
d
e
0
.0
5
4
–
3
9
.7
0
0
n
g
m
l2
1
0
.0
9
0
n
g
m
l2
1
L
9
.0
%
;
M
8
.7
%
;
H
1
0
.2
%
L
2
.8
%
;
M
5
.7
%
;
H
1
4
.7
%
C
a
l-
B
io
te
ch
0
.2
0
–
9
.8
0
n
g
m
l2
1
0
.0
4
5
n
g
m
l2
1
3
.9
%
1
0
.8
%
2
7
(c
a
li
b
)
lo
g
y
5
0
.7
2
2
(l
og
x)
1
0
.7
0
6
0
.9
3
4
*
E
1
G
0
.7
1
6
–
5
2
2
.0
0
0
n
g
m
l2
1
0
.2
5
2
n
g
m
l2
1
L
11
.3
%
;
M
9
.5
%
;
H
8
.2
%
L
8
.4
%
;
M
6
.5
%
;
H
9
.7
%
In
-h
ou
se
E
IA
0
.3
1
2
5
–
4
0
.0
n
g
m
l2
1
1
.4
5
n
g
m
l2
1
L
3
.6
%
;
H
1
2
.2
%
L
3
.2
%
;
H
1
3
.7
%
3
3
(c
a
li
b
)
lo
g
y
5
1
.4
0
3
(l
og
x)
1
0
.4
1
8
0
.9
4
0
*
B
a
y
er
A
C
S
:1
8
0
(E
1
C
)
5
.1
–
4
0
8
.0
n
g
m
l2
1
0
.1
n
g
m
l2
1
3
.8
%
6
.5
%
3
3
5
(a
rc
h
iv
)
lo
g
y
5
1
.7
4
5
(l
og
x)
–
0
.3
1
9
0
.9
1
4
*
F
S
H
-b
et
a
0
.0
2
3
–
1
6
.7
2
0
n
g
m
l2
1
0
.0
1
7
n
g
m
l2
1
L
4
.4
%
;
M
5
.5
%
;
H
11
.7
%
L
8
.3
%
;
M
4
.6
%
;
H
9
.0
%
In
-h
ou
se
IE
M
A
0
.1
2
5
–
8
.0
n
g
m
l2
1
0
.1
4
3
n
g
m
l2
1
L
3
.9
%
;
M
4
.6
%
;
H
5
.6
%
L
1
4
.5
%
;
M
1
4
.5
%
;
H
1
7
.0
%
3
1
(c
a
li
b
)
lo
g
y
5
0
.6
0
1
(l
og
x)
1
0
.2
1
2
0
.6
9
4
*
0
.2
2
9
–
1
6
7
.2
0
0
m
IU
m
l2
1
0
.1
7
1
m
IU
m
l2
1
B
a
y
er
A
C
S
:1
8
0
0
.3
–
1
4
4
.0
m
IU
m
l2
1
0
.3
m
IU
m
l2
1
2
.3
%
5
.8
%
3
7
1
(a
rc
h
iv
)
lo
g
y
5
0
.8
3
6
(l
og
x)
1
0
.3
4
5
0
.8
9
0
*
h
C
G
-b
et
a
0
.0
5
8
–
4
2
.5
0
0
n
g
m
l2
1
0
.0
3
5
n
g
m
l2
1
L
4
.7
%
;
M
5
.6
%
;
H
11
.1
%
L
4
.1
%
;
M
5
.4
%
;
H
1
3
.4
%
B
a
y
er
A
C
S
:1
8
0
0
.0
0
3
–
1
.0
n
g
m
l2
1
0
.0
0
3
n
g
m
l2
1
3
.5
%
5
.8
%
3
4
2
(a
rc
h
iv
)
lo
g
y
5
0
.3
2
2
(l
og
x)
-
0
.2
3
5
0
.4
2
7
*
A
ss
a
y
s
a
re
co
n
si
d
er
ed
si
m
il
a
r
if
th
e
re
g
re
ss
io
n
a
n
a
ly
si
s
is
si
g
n
iﬁ
ca
n
t
(P
<
0
.0
5
)
a
n
d
th
e
P
ea
rs
on
co
rr
el
a
ti
on
co
ef
ﬁ
ci
en
t
(r
)
is

0
.7
5
.
Q
u
a
n
sy
s
a
ss
a
y
se
n
si
ti
v
it
ie
s
a
re
re
p
or
te
d
a
s
th
e
lo
w
er
li
m
it
of
d
et
ec
ti
on
(L
D
D
)
w
h
ic
h
is
b
a
se
d
on
th
e
m
ea
n
p
lu
s
tw
o-
ti
m
es
th
e
st
a
n
d
a
rd
d
ev
ia
ti
on
of
th
e
n
on
-s
p
ec
iﬁ
c
b
in
d
in
g
sa
m
p
le
te
st
ed
2
0
ti
m
es
.
Q
u
a
n
sy
s
a
ss
a
y
p
re
ci
si
on
is
re
p
or
te
d
a
s
in
tr
a
-a
ss
a
y
(2
0
re
p
li
ca
te
s
of
a
lo
w
-
(L
),
m
id
d
le
-
(M
),
a
n
d
h
ig
h
-c
on
ce
n
tr
a
ti
on
(H
)
sa
m
p
le
)
a
n
d
in
te
r-
a
ss
a
y
(l
ow
-,
m
id
d
le
-,
a
n
d
h
ig
h
-c
on
ce
n
tr
a
ti
on
sa
m
p
le
s
ru
n
in
d
u
p
li
ca
te
a
cr
os
s
2
0
p
la
te
s)
co
ef
ﬁ
ci
en
t
of
v
a
ri
a
ti
on
.
S
en
si
ti
v
it
ie
s
of
th
e
in
-h
ou
se
a
ss
a
y
s
(E
1
G
,
F
S
H
-b
et
a
)
a
re
re
p
or
te
d
a
s
th
e
lo
w
es
t
d
os
e
g
iv
in
g
re
su
lt
s
th
a
t
a
re
si
g
n
iﬁ
ca
n
tl
y
d
if
fe
re
n
t
fr
om
ze
ro
(P
<
0
.0
5
)
b
a
se
d
on
d
u
p
li
ca
te
w
el
ls
in
2
0
p
la
te
s.
P
re
ci
si
on
v
a
lu
es
of
th
e
in
-h
ou
se
a
ss
a
y
s
p
re
ci
-
si
on
w
er
e
ca
lc
u
la
te
d
a
cr
os
s
1
0
(F
S
H
-b
et
a
)
or
2
0
(E
1
G
)
p
la
te
s.
S
en
si
ti
v
it
y
a
n
d
p
re
ci
si
on
v
a
lu
es
fo
r
th
e
in
d
iv
id
u
a
l,
co
m
m
er
ci
a
ll
y
-a
v
a
il
a
b
le
im
m
u
n
oa
ss
a
y
s
a
re
p
ro
v
id
ed
b
y
th
e
m
a
n
u
fa
ct
u
re
r.
n
5
sa
m
p
le
si
ze
.
U
ri
n
e
se
t
in
d
ic
a
te
s
w
h
et
h
er
th
e
ca
li
b
ra
ti
on
(c
a
li
b
)
or
a
rc
h
iv
ed
(a
rc
h
iv
)
u
ri
n
e
sa
m
p
le
s
w
er
e
u
se
d
fo
r
a
n
a
ly
si
s.
F
or
a
ll
tr
en
d
li
n
es
,
y
5
Q
u
a
n
sy
s
v
a
lu
es
a
n
d
x
5
in
d
iv
id
u
a
l
im
m
u
n
oa
ss
a
y
v
a
lu
es
.
*
P
<
0
.0
0
0
1
.
Assay comparison and statistical analysis
The biomarker results from the multiplex assay and the
individual immunoassays were not normally distributed.
Therefore, they were log-transformed prior to comparison
using linear regression (JMP, version 8, SAS Corporation,
Cary, NC) and Bland-Altman analysis (Bland and Altman,
1999). Samples whose concentrations fell below the sensitiv-
ity of the Quansys or individual assay were not included in
the analysis, resulting in different sample sizes across ana-
lytes. The assays were considered similar if the correlation
between the assays was signiﬁcant (two-tailed P-value
<0.05) and the Pearson correlation coefﬁcient (r) was0.75.
We also determined whether the multiplex array
returned hormone proﬁle patterns consistent with the
individual immunoassays by plotting and comparing log-
transformed cortisol, E1G, FSH-beta, and hCG-beta pro-
ﬁles measured using both the Quansys multiplex and the
Bayer ACS:180 assays.
RESULTS AND DISCUSSION
Pearson correlation coefﬁcients and the equations for
the best-ﬁt lines are presented for all of the hormones in
Table 1. Linear regression analysis indicated that ﬁve of
the multiplexed assays were not statistically different
from the established individual immunoassays (Table 1;
Fig. 1).
One comparison, between the multiplex assay and the in-
house immunoassay for FSH-beta, fell below our predeter-
mined correlation coefﬁcient threshold (r 5 0.694 < 0.75;
Table 1; Fig. 1G). This relatively weaker correlation could be
the result of using different antibody pairs that recognize
different epitopes on the relatively large FSH-betamolecule.
Furthermore, the use of different antigen standards in the
multiplex and individual FSH-beta immunoassays may
have also inﬂuenced the absolute values of the results. The
multiplex uses intact FSH as the standard for the FSH-beta
assay (with antibodies directed against FSH-beta), while
the in-house IEMA uses FSH-beta as the standard. In con-
trast, the multiplex FSH-beta assay was highly correlated
with the Bayer ACS:180 FSH-beta assay (Table 1; Fig. 1H).
When all of the data for hCG-beta were included (n 5
362), the Quansys multiplex and Bayer hCG-beta assays
were highly correlated (r 5 0.878; P < 0.001). However,
the Bayer assay had a more limited range than the multi-
plex assay (Table 1). Subsequently, while the levels of
Fig. 1. Linear regressions of the log-transformed results from each of the six hormones measured using the multiplex assay versus the corre-
sponding results obtained from the individual immunoassays. Each individual immunoassay comparison is shown on a separate graph (A–I).
The size of each point is proportional to the number of urine samples it represents.
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hCG-beta associated with pregnancy maintenance were
measurable by the multiplex assay, they maxed out the
Bayer assay and are reported as the maximum value of
the assay’s range (1.0 ng ml21 hCG-beta). This resulted in
two distinct groups of Bayer hCG-beta data: low values
representing samples from non- or newly-pregnant
women and high values representing samples from preg-
nant women. When only the data from non- or newly-
pregnant women were included in the analysis (i.e., data
within the measurable range of both assays; n 5 342) the
correlation between the two assays was signiﬁcant, but
fell below our predetermined correlation coefﬁcient
threshold (r 5 0.427 < 0.75; Table 1; Fig. 1I). Thus, the
hCG-beta assay was the only multiplexed assay that dif-
fered from the corresponding individual immunoassay.
The use of different antibody pairs that recognize different
epitopes on the hCG-beta molecule may explain the rela-
tively weaker correlation we observed between the hCG-
beta immunoassays. Therefore, for hCG-beta, hormone
proﬁle assessment (below) may be a more appropriate
comparison between the two assays.
Bland–Altman analysis shows the magnitude of the dif-
ferences between the multiplex and individual immunoas-
says for each biomarker (Fig. 2). The urinary biomarker
results from the individual immunoassays were consis-
tently lower than the corresponding concentrations meas-
ured by the multiplex assay, but the differences were gen-
erally consistent across the hormone concentration
ranges, with a few exceptions. When comparing the multi-
plexed E1G assay with both the in-house E1G EIA and
the Bayer ACS:180 E1C immunoassay (Fig. 2E, F, respec-
tively), there was an increase in the difference between
the assays as the magnitude of E1G concentration
increased, but no corresponding change in the variability
of the differences. In contrast, there was an increase in
the variability of the differences as the magnitude of FSH-
beta concentration decreased in comparison between uri-
nary FSH-beta as measured by multiplex and the Bayer
ACS:180 immunoassay (Fig. 2H).
Free cortisol, E1G, FSH-beta, and hCG-beta proﬁles
obtained for a representative participant measured using
the multiplex and Bayer assays are shown in Figure 3.
Fig. 2. Bland–Altman plots of the differences between log-transformed urinary biomarker concentration measured by the multiplex and indi-
vidual immunoassays plotted against the average log-transformed urinary biomarker concentration. Each individual immunoassay comparison
is shown on a separate graph (A–I). Each point represents a urine sample. The center solid line indicates the mean difference. The upper and
lower solid lines indicate the 95% conﬁdence intervals, or limits of agreement. The dashed line indicates the line of equality.
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The multiplex and Bayer ACS:180 immunoassays
resulted in similar temporal patterns for urinary free cor-
tisol (Fig. 3A), E1G (Fig. 3B), FSH-beta (Fig. 3C), and
hCG-beta (Fig. 3D), with similar peaks and troughs
throughout the sampling period. These results were simi-
lar for the other 14 participants. As both methods consis-
tently detected the same patterns in the excretion rates of
all four hormones, both assays are valid when assessing
temporal changes in these hormones.
Our validation results conﬁrm that the Quansys multi-
plex female array is a valid alternative to individual
immunoassays for the quantiﬁcation of adiponectin, free
cortisol, c-peptide, E1G, FSH-beta, and hCG-beta in
human urine samples and can be used to assess daily
changes in the urinary excretion of these hormones and
their dynamic interactions. This multiplex technology pro-
vides a more economic, rapid, and ecologically sound alter-
native to individual assays for studies requiring the mea-
surement of multiple biomarkers per biospecimen.
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Fig. 3. Free cortisol (A), E1G (B), FSH-beta (C), and hCG-beta (D) proﬁles for subject 3 as determined by Bayer ACS:180 (~) and Quansys
multiplex (~) immunoassays.
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